Classification and risk stratification are crucial for the management and treatment of patients with myelodysplastic syndromes (MDS). For many years, the gold standard for assessing disease risk has been the Revised International Prognostic Scoring System (IPSS-R). However, the recently-developed IPSS-Molecular (IPSS-M) has been evaluated and provides valuable information, improving overall risk assessment.
In this podcast, leading experts Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, Aziz Nazha, MD, Amazon Web Services, Westlake, OH, Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, and Jane Churpek, MD, MS, University of Wisconsin School of Medicine, Madison, WI, discuss updates in classification and risk stratification in MDS, including the value of the novel IPSS-M and the MDS Clinical Research Consortium Molecular Prognostic Tool. This discussion took place at the 1st International Workshop on Myelodysplastic Syndromes (iwMDS) held in Miami, FL.
The post Updates in classification and risk stratification in MDS appeared first on VJHemOnc.
